Drug Discovery Services Market research report Forecast to 2030 Market Overview The Drug Discovery Services market industry is projected to exhibit a significant CAGR of 13.92% during the forecast period. Developing Re-appropriating of Drug Advancement and Expanding Exploration and Improvement Expenses are the key market drivers upgrading the Drug Discovery Services market development. Drug and biopharmaceutical organizations are picking completely coordinated or practical rethinking services for drug innovative work from the early improvement stage to the late-stage advancement stage due to expanded Research and development consumptions. While drug organizations are under extraordinary strain to monitor fixed costs, re-appropriating has arisen as a strategic answer for the absence of inside assets required for new item improvement. Enormous pharma firms are changing to a more streamlined corporate methodology that unequivocally stresses rethinking. Expanding need for imaginative therapeutics across a scope of restorative objectives. Drug-finding services Rising requirement for imaginative therapies for constant sicknesses and headways in the medical care industry are anticipated to be the primary drivers of market development. Drug and biopharmaceutical organizations actually contract their innovative work (Research and Development) activities to CROs, who offer Research and development services and make commitment models to boost Research and development productivity. Legislatures and drug enterprises are compelled to search for answers and lift their interest in clinical preliminaries because of the expanded weight of persistent sicknesses. Subsequently, there will be a more prominent requirement for drug discovery services. Market Segmentation Based on Drug Type, the Drug Discovery Services market has been classified into Small Molecule Drugs, Biologics’ Based on type, the market is divided into Drug metabolism and pharmacokinetics (DMPK) Services, Pharmaceutical Services, and Others. Therapeutic Areas of the Drug Discovery Services market are bifurcated into data into Oncology, Others. Regional Analysis North America is likely to drive the global Drug Discovery Services market due to the higher interest in drug discovery Research and development, critical firms with laid-out research foundations, and specialized upgrades. As rethinking is at this point not just about reducing expenses, a developing requirement for viability, quality, and development is expected to help industry extension. The Asia Pacific drug discovery services market is anticipated to develop the highest growth owing to the accessibility of qualified individuals, less expensive costs, a successful administrative climate, and great information, the Region is rapidly turning into a center for re-appropriating drug improvement exercises. The second-biggest drug market on the planet, Japan, is expected to furnish CROs with a sizable potential, driving the business. The fast improvement of innovation and the development of metropolitan regions impel the European drug discovery services market. The improvement of biologics and biosimilars has seen an expansion in speculation from biopharmaceutical firms, which is liable for the ascent in the number of approved drugs in Europe. The European drug discovery services market is expected to be driven by expanding consumptions made by many significant organizations in different clinical and non-clinical examination exercises that are moved to a few CRO specialist co-ops and help with proficient item improvement. Major Players Abbott Laboratories Inc., Advinus Therapeutics, Albany Molecular Research Inc. (AMRI), Aurigene, Agilent Technologies Ubiquigent, AstraZeneca PLC, Retrogenix (U.K.), Charles River Laboratories International, Eurofins, and Liverpool ChiroChem Ltd.

1 EXECUTIVE SUMMARY 1.1 OVERVIEW 2 MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.3 RESEARCH OBJECTIVE 2.4 MARKET STRUCTURE 2.5 ASSUMPTIONS & LIMITATIONS 3 RESEARCH METHODOLOGY 3.1 DATA MINING 3.2 SECONDARY RESEARCH 3.3 PRIMARY RESEARCH 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 INCREASING RESEARCH & DEVELOPMENT EXPENDITURE 4.2.2 RISING DRUG DEVELOPMENT OUTSOURCING 4.3 RESTRAINTS 4.3.1 STRINGENT REGULATORY POLICIES AND COSTS ASSOCIATED TO DRUG DISCOVERY 4.4 OPPORTUNITY 4.4.1 TECHNOLOGICAL ADVANCEMENTS IN DRUG DISCOVERY 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY) 5.1.2 SERVICE CUSTOMIZATION 5.1.2.1 R&D 5.1.2.2 GOOD LABORATORY PRACTICES (GLP) 5.1.3 CUSTOMER PURCHASE SUPPORT 5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT 5.2 PORTER'S FIVE FORCES MODEL 5.2.1 THREAT OF NEW ENTRANTS 5.2.2 BARGAINING POWER OF SUPPLIERS 5.2.3 THREAT OF SUBSTITUTES 5.2.4 BARGAINING POWER OF BUYERS 5.2.5 INTENSITY OF RIVALRY 5.3 COVID-19 IMPACT ON THE DRUG DISCOVERY SERVICES MARKET 5.3.1 IMPACT ON R&D 5.3.2 IMPACT ON PRICING 5.3.3 IMPACT ON MARKET GROWTH 6 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 6.1 OVERVIEW 6.2 SMALL MOLECULE DRUG 6.3 BIOLOGICS DRUG 7 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TYPES OF SERVICES 7.1 OVERVIEW 7.2 DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES 7.3 PHARMACEUTICAL SERVICES 7.4 MEDICINAL CHEMISTRY 7.5 BIOLOGICAL SERVICES 7.6 MEDICATION 8 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 8.1 OVERVIEW 8.2 ONCOLOGY 8.3 CARDIOVASCULAR DISEASES 8.4 RESPIRATORY DISEASES 8.5 DIABETES 8.6 OTHERS 9 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TECHNOLOGY 9.1 OVERVIEW 9.2 HIGH THROUGHPUT SCREENING 9.3 BIOCHIPS 9.4 PHARMACOGENOMICS AND PHARMACOGENETICS 9.5 METABOLOMICS 9.6 OTHERS 10 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY END USER 10.1 OVERVIEW 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 10.3 RESEARCH & ACADEMIC INSTITUTES 10.4 OTHERS 11 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY REGION 11.1 OVERVIEW 11.2 NORTH AMERICA 11.2.1 US 11.2.2 CANADA 11.3 EUROPE 11.3.1 GERMANY 11.3.2 FRANCE 11.3.3 UK 11.3.4 ITALY 11.3.5 SPAIN 11.3.6 REST OF EUROPE 11.4 ASIA-PACIFIC 11.4.1 CHINA 11.4.2 JAPAN 11.4.3 INDIA 11.4.4 AUSTRALIA 11.4.5 SOUTH KOREA 11.4.6 REST OF ASIA-PACIFIC 11.5 REST OF THE WORLD 11.5.1 MIDDLE EAST 11.5.2 AFRICA 11.5.3 LATIN AMERICA 12 COMPETITIVE LANDSCAPE 12.1 OVERVIEW 12.2 COMPETITIVE BENCHMARKING 12.3 MAJOR GROWTH STRATEGY IN DRUG DISCOVERY SERVICES MARKET 12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN DRUG DISCOVERY SERVICES MARKET 12.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 12.5.1 SERVICE LAUNCH 12.5.2 MERGERS & ACQUISITIONS 12.5.3 PARTNERSHIP/COLLABORATION 12.6 MAJOR PLAYERS SALES ANALYSIS 12.6.1 SALES & OPERATING INCOME, 2021 (USD MILLION) 12.6.2 MAJOR PLAYERS R&D ANALYSIS, 2021 (USD MILLION) 13 COMPANY PROFILE 13.1 THERMO FISHER SCIENTIFIC INC 13.1.1 COMPANY OVERVIEW 13.1.2 FINANCIAL OVERVIEW 13.1.3 SERVICES OFFERED 13.1.4 KEY DEVELOPMENTS 13.1.5 SWOT ANALYSIS 13.1.6 KEY STRATEGIES 13.2 ARAGEN LIFE SCIENCES PVT. LTD 13.2.1 COMPANY OVERVIEW 13.2.2 FINANCIAL OVERVIEW 13.2.3 SERVICES OFFERED 13.2.4 KEY DEVELOPMENTS 13.2.5 KEY STRATEGIES 13.3 PIRAMAL PHARMA SOLUTIONS 13.3.1 COMPANY OVERVIEW 13.3.2 FINANCIAL OVERVIEW 13.3.3 SERVICES OFFERED 13.3.4 KEY DEVELOPMENTS 13.3.5 KEY STRATEGIES 13.4 CURIA GLOBAL, INC 13.4.1 COMPANY OVERVIEW 13.4.2 FINANCIAL OVERVIEW 13.4.3 SERVICES OFFERED 13.4.4 KEY STRATEGIES 13.5 CHARLES RIVER LABORATORIES 13.5.1 COMPANY OVERVIEW 13.5.2 FINANCIAL OVERVIEW 13.5.3 SERVICES OFFERED 13.5.4 KEY DEVELOPMENTS 13.5.5 SWOT ANALYSIS 13.5.6 KEY STRATEGIES 13.6 EUROFINS SCIENTIFIC 13.6.1 COMPANY OVERVIEW 13.6.2 FINANCIAL OVERVIEW 13.6.3 SERVICES OFFERED 13.6.4 KEY DEVELOPMENTS 13.6.5 SWOT ANALYSIS 13.6.6 KEY STRATEGIES 13.7 IQVIA 13.7.1 COMPANY OVERVIEW 13.7.2 FINANCIAL OVERVIEW 13.7.3 SERVICES OFFERED 13.7.4 KEY DEVELOPMENTS 13.7.5 SWOT ANALYSIS 13.7.6 KEY STRATEGIES 13.8 EVOTEC 13.8.1 COMPANY OVERVIEWS 13.8.2 FINANCIAL OVERVIEW 13.8.3 SERVICES OFFERED 13.8.4 KEY DEVELOPMENTS 13.8.5 KEY STRATEGIES 13.9 WUXI APPTEC CO., LTD 13.9.1 COMPANY OVERVIEW 13.9.2 FINANCIAL OVERVIEW 13.9.3 SERVICES OFFERED 13.9.4 KEY DEVELOPMENTS 13.9.5 SWOT ANALYSIS 13.9.6 KEY STRATEGIES 13.10 LABORATORY CORPORATION OF AMERICA HOLDINGS 13.10.1 COMPANY OVERVIEW 13.10.2 SERVICES OFFERED 13.10.3 KEY DEVELOPMENTS 13.10.4 KEY STRATEGIES 13.11 SELVITA 13.11.1 COMPANY OVERVIEW 13.11.2 FINANCIAL OVERVIEW 13.11.3 SERVICES OFFERED 13.11.4 KEY DEVELOPMENTS 13.11.5 SWOT ANALYSIS 13.11.6 KEY STRATEGIES 13.12 SYGNATURE DISCOVERY 13.12.1 COMPANY OVERVIEW 13.12.2 FINANCIAL OVERVIEW 13.12.3 SERVICES OFFERED 13.12.4 KEY DEVELOPMENTS 13.12.5 SWOT ANALYSIS 13.12.6 KEY STRATEGIES 13.13 SYMERES 13.13.1 COMPANY OVERVIEW 13.13.2 FINANCIAL OVERVIEW 13.13.3 SERVICES OFFERED 13.13.4 KEY DEVELOPMENTS 13.13.5 SWOT ANALYSIS 13.13.6 KEY STRATEGIES 13.14 NUCHEM SCIENCES INC 13.14.1 COMPANY OVERVIEW 13.14.2 FINANCIAL OVERVIEW 13.14.3 SERVICES OFFERED 13.14.4 KEY STRATEGIES 13.15 PARAZA PHARMA, INC 13.15.1 COMPANY OVERVIEW 13.15.2 FINANCIAL OVERVIEW 13.15.3 SERVICES OFFERED 13.15.4 KEY DEVELOPMENTS 13.15.5 KEY STRATEGIES 14 APPENDIX 14.1 REFERENCES 14.2 RELATED REPORTS